Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Precancerous Condition: early-phase trial registry

2 of 19 indexed Precancerous Condition trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #902 of 28,707 conditions by registered trial count.

19 US clinical trials · 2 currently recruiting · #902 of 28,707 conditions by registered trial count

Precancerous Condition: 19 US clinical trials tracked, 2 recruiting.

Precancerous Condition is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 3 of these trials.

Enrollment posture brief

Registry condition precancerous-condition

OPEN 2 | RECR 11% | LATE 3 | EARLY 7 | RANK #902 | SPON 3

Nearest open-share peer: Vitamin D Deficiency (10% recruiting · 49 trials)

Amyotrophic Lateral Sclerosi52.6%Anesthesia, Local42.1%Alcohol Consumption36.8%Attention Deficit Hyperactiv26.3%Precancerous Condition (this)11%
Open-enrollment share among volume-matched conditions near Precancerous Condition

Precancerous Condition lists 2 open slots (11% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Precancerous Condition on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Precancerous Condition is recruiting below its size-band peers.

    2 of 19 indexed trials (10.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Precancerous Condition research.

    University of Colorado, Denver accounts for 3 of 19 trials (15.8%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Typical Precancerous Condition enrolment sits around 152 participants.

    Median target enrolment is 152 among the 16 trials that report a genuine target (sentinel values excluded). 7 of those (43.8%) plan for fewer than 100 participants.

  4. Precancerous Condition splits between interventional and observational designs.

    12 interventional and 7 observational studies make up this index (63.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 25Phase 33

Open and recent trials

19 total, page 1 of 1

RECRUITING 5,000 participants

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients

Vanderbilt University Medical Center

NCT00899626

RECRUITING 700 participants

Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

University of Colorado, Denver

NCT00900419

COMPLETED Phase 3 987 participants

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Radiation Therapy Oncology Group

NCT01302834

COMPLETED NA 684 participants

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

Gynecologic Oncology Group

NCT00003384

COMPLETED Phase 3 502 participants

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Mayo Clinic

NCT00661999

COMPLETED 375 participants

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

SWOG Cancer Research Network

NCT00900263

COMPLETED Phase 2 368 participants

Folic Acid Clinical Trial for the Prevention of Cervical Cancer

University of Alabama at Birmingham

NCT00703196

COMPLETED Phase 2 152 participants

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

NCT00084409

COMPLETED 112 participants

Biomarkers in the Nose, Throat, and Lung Tissue of Smokers and Non-Smokers

University of Colorado, Denver

NCT00897364

COMPLETED Phase 3 98 participants

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Vanderbilt-Ingram Cancer Center

NCT00666211

COMPLETED 97 participants

Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging

Children's Oncology Group

NCT00445718

COMPLETED 82 participants

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

AIDS Malignancy Consortium

NCT01946217

COMPLETED Phase 2 80 participants

Lovastatin in Treating Patients At High Risk of Melanoma

National Cancer Institute (NCI)

NCT00462280

COMPLETED Phase 2 50 participants

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

National Cancer Institute (NCI)

NCT00841204

COMPLETED Phase 2 32 participants

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

NCT00589563

COMPLETED NA 16 participants

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

OHSU Knight Cancer Institute

NCT00627276

COMPLETED Phase 1

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Boston Medical Center

NCT00006340

COMPLETED

Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II

National Cancer Institute (NCI)

NCT00099112

COMPLETED Phase 1

PS-341 in Treating Patients With Advanced Cancer

Mayo Clinic

NCT00006362

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 3

Named interventions

Most-linked intervention names on Precancerous Condition records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

placebo Other
6 trials
biopsy Procedure
3 trials
laboratory biomarker analysis Other
3 trials
questionnaire administration Other
2 trials
microarray analysis Genetic
2 trials
sodium ferric gluconate complex in sucrose Drug
1 trials
ferrous sulfate Dietary supplement
1 trials
darbepoetin alfa Biological
1 trials

US sites by state

Facility locations filed on Precancerous Condition trials. A trial with sites in several states counts in each.

California 7 trials
Colorado 5 trials
Arizona 5 trials
Tennessee 3 trials
New York 3 trials
Minnesota 3 trials
Massachusetts 3 trials
Illinois 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Precancerous Condition page

19 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Precancerous Condition condition card totals 19 registered trials; most-linked intervention placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.